Brokerages Set Phibro Animal Health Corporation (NASDAQ:PAHC) Target Price at $31.40

Phibro Animal Health Corporation (NASDAQ:PAHC) has been given an average recommendation of “Hold” by the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $31.40.

A number of research analysts have recently commented on the company. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Tuesday. Bank of America boosted their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, August 29th. JPMorgan Chase & Co. upped their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Morgan Stanley set a $34.00 target price on shares of Phibro Animal Health in a research note on Thursday, August 28th.

Phibro Animal Health Price Performance

PAHC opened at $45.10 on Thursday. The firm has a 50-day moving average of $40.43 and a 200 day moving average of $31.89. The firm has a market cap of $1.83 billion, a P/E ratio of 38.22, a PEG ratio of 1.24 and a beta of 0.81. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. Phibro Animal Health has a fifty-two week low of $16.16 and a fifty-two week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, research analysts expect that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio is presently 28.92%.

Insider Activity

In other news, CEO Jack Bendheim sold 8,801 shares of Phibro Animal Health stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $44.47, for a total transaction of $391,380.47. Following the sale, the chief executive officer directly owned 5,240 shares of the company’s stock, valued at approximately $233,022.80. The trade was a 62.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 139,496 shares of company stock valued at $5,985,651 in the last ninety days. 50.13% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of the stock. Financial Management Professionals Inc. bought a new stake in shares of Phibro Animal Health in the 2nd quarter valued at about $32,000. National Bank of Canada FI bought a new position in shares of Phibro Animal Health during the 1st quarter worth $30,000. iSAM Funds UK Ltd bought a new position in shares of Phibro Animal Health in the third quarter worth $61,000. EverSource Wealth Advisors LLC lifted its stake in shares of Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after acquiring an additional 2,685 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Phibro Animal Health by 768.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after purchasing an additional 4,079 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.